A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemochromatosis; Iron overload
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 06 Jun 2024 Status changed from completed to discontinued.
- 17 May 2023 Status changed from active, no longer recruiting to completed.
- 17 Apr 2023 Planned End Date changed from 18 Apr 2023 to 24 Apr 2023.